KRS Capital Management LLC Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

KRS Capital Management LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,602 shares of the company’s stock after selling 97 shares during the quarter. KRS Capital Management LLC’s holdings in Johnson & Johnson were worth $376,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in JNJ. Gill Capital Partners LLC grew its stake in Johnson & Johnson by 14.8% in the 4th quarter. Gill Capital Partners LLC now owns 2,168 shares of the company’s stock worth $314,000 after acquiring an additional 279 shares in the last quarter. CGN Advisors LLC lifted its position in shares of Johnson & Johnson by 8.7% during the fourth quarter. CGN Advisors LLC now owns 27,217 shares of the company’s stock valued at $3,936,000 after buying an additional 2,169 shares during the last quarter. Premier Path Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 34.4% in the 4th quarter. Premier Path Wealth Partners LLC now owns 16,074 shares of the company’s stock worth $2,325,000 after purchasing an additional 4,111 shares in the last quarter. Howard Financial Services LTD. grew its position in Johnson & Johnson by 34.3% during the 4th quarter. Howard Financial Services LTD. now owns 4,950 shares of the company’s stock worth $716,000 after purchasing an additional 1,265 shares during the last quarter. Finally, Alhambra Investment Management LLC raised its stake in Johnson & Johnson by 1.3% in the 4th quarter. Alhambra Investment Management LLC now owns 9,087 shares of the company’s stock worth $1,314,000 after acquiring an additional 120 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on JNJ. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Wolfe Research began coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Bank of America cut their price objective on shares of Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a report on Friday. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Royal Bank of Canada increased their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $174.29.

Johnson & Johnson Trading Down 0.5 %

Shares of JNJ opened at $147.03 on Monday. The firm’s fifty day moving average is $148.51 and its two-hundred day moving average is $156.03. The stock has a market cap of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.